Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
All peptides

ARA-290

Also known as: Cibinetide
Research / Investigational

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the tissue-protective helix B of erythropoietin, engineered to lack hematopoietic activity.

Buy ARA-290 on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the tissue-protective helix B of erythropoietin, engineered to lack hematopoietic activity.

FDA Approval Status

Not approved by the FDA. Investigational or intended for research purposes only.

Mechanism of Action

Activates the innate repair receptor (heteromer of EPOR and CD131) to reduce inflammation and support repair.

Current Research

Phase II trials in sarcoid small-fiber neuropathy and diabetic neuropathy.
Research strength: Moderate

Potential Medical Uses

  • Investigational only

Potential Benefits

  • Reported improvement in neuropathic pain and small-fiber function

Known Side Effects

  • Injection-site reactions
  • Overall well tolerated in trials

Contraindications

  • Pregnancy

Drug Interactions

  • Not well characterized

Administration Methods

  • Subcutaneous injection

Half-life

~2 minutes (rapid tissue distribution)

Reconstitution

Bacteriostatic water.

Storage & Handling

Refrigerated.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.